Roumell Asset Management Dumps Tecumseh Products Company (TECUA)

Roumell Asset Management, led by Jim Roumell, revealed in a filing with Securities and Exchange Commission that it has dumped its holding in Tecumseh Products Company (NASDAQ:TECUA).  The fund held 523,024 Class A Shares and 334,778 Class B Shares of the company previously.

Tecumseh Products Company

Tecumseh Products Company (NASDAQ:TECUA), manufactures hermetically sealed compressors. Recently, Tecumseh Products announced its expansion of AE2 line-up for low-to-medium back pressure (L/MBP) applications. Tecumseh Products will also be benefited with its new Masterflux® Eclipse direct current compressors and Sierra chiller units.

Nierenberg Investment Management, led by David Nierenberg, initiated a position in Tecumseh Products Company (NASDAQ:TECUA) in the third quarter of 2013, and held 1.16 million shares at the end of the quarter, with a reported value of $9.99 million. Jim Simons’ Renaissance Technologies, held 448,200 shares of Tecumseh, worth $4.01 million.

Roumell Asset Management focuses on “finding value through out-of-favor, overlooked or misunderstood securities.” The fund has 13.16% of its equity portfolio invested in Apple Inc. (NASDAQ:AAPL), and held 33,922 shares of the company at the end of the third quarter of 2013. TETRA Technologies, Inc. (NYSE:TTI), stands on the second spot, the fund holding 1.11 million shares. In Ultra Petroleum Corp. (NYSE:UPL), the fund held 499,140 shares.

Last month, Roumell Asset Management dumped around 450,000 shares of QAD Inc. (NASDAQ:QADA) and approximately 600,000 million shares of Dover Motorsports, Inc. (NYSE DVD).

Joel Ramin’s 12 West Capital Discloses New Passive Stake in Zulily Inc (ZU)

Charles Paquelet’s Skylands Capital Is Bullish On These Stocks

Vollero Beach Capital Reveals A Large Position in Goodrich Petroleum Corporation (GDP)

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!